Fourth-generation allosteric EGFR inhibitors: Structure-based scaffold analysis and SAR exploration

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• C797S mutation in EGFR-mutant non-small cell lung cancer confers resistance to third-generation tyrosine kinase inhibitors.
• Standard orthosteric inhibitors are ineffective against this resistance.
• Allosteric inhibitors target a distinct binding site, offering a novel approach to overcome resistance.

Purpose of the Study:

• To comprehensively review the medicinal chemistry of allosteric Epidermal Growth Factor Receptor (EGFR) inhibitors over the past decade.
• To identify key design principles for developing potent allosteric EGFR inhibitors.
• To assess the clinical viability of allosteric EGFR inhibition for treating resistant non-small cell lung cancer.

Main Methods:

• Systematic review of published literature on allosteric EGFR inhibitor medicinal chemistry.
• Analysis of 185 compounds across eight scaffold classes.
• Structure-activity relationship (SAR) analysis to identify design principles for allosteric potency.

Main Results:

• The aminothiazole scaffold is dominant, followed by 4-anilinoquinazoline.
• Five universal design principles for allosteric potency were identified: hydrogen bond network, hydrophobic pocket complementarity, bivalent binding, precise linker geometry, and core heterocycle identity.
• Eleven compounds achieved ultra-nanomolar potency (IC₅₀ < 1 nM), with the aminothiazole-isoindolinone hybrid achieving 0.10 nM.

Conclusions:

• Allosteric EGFR inhibition is a clinically viable strategy to overcome osimertinib resistance in non-small cell lung cancer.
• Lead candidates with demonstrated potency are ready for clinical translation.
• The identified design principles provide a roadmap for future development of allosteric EGFR inhibitors.